BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 12/06/22

Jerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune ...

BiondVax Pharmaceuticals (NASDAQ: BVXV) , a biotech company that focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its third quarter, the period ending Sept. 30, 2022; t...

JERUSALEM, Nov. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today p...

In collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, BiondVax is developing a pipeline of NanoAb therapies The company’s co-lead scientific research collaborator, Professor Dr. Dirk G...

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today announced statistically significant (p<0.001) efficacy r...

Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with inhaled placebo BiondVax’s nanosized antibodies (NanoAbs) are being formula...

BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psori...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the upcoming Biotech...

BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco PR Newswire JERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and co...

The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet m...